How They Discredit You
We muse on the importance of retaining credibility when standing up to false opioid narratives.
Narratives on the Opioid Crisis
We propose new rules for journalists to integrate statistics on opioids and related overdoses into their stories.
Thank you, AHCJ!
We reflect on our experiences at the recent Association of Health Care Journalists conference in St. Louis.
Confronting My Fears
I discuss my continuing struggles to overcome self-doubt and share some techniques that have proved effective.
In Support of IL HB 2046
The Illinois state assembly should support IL HB 2046, which requires a warrant prior to investigating a provider’s prescription database.
Media Sensationalism in the Opioid Epidemic
We describe in detail how sensationalism around the coverage of the opioid epidemic and the mounting overdoses takes on a...
Why I Had Dr. Ruan Speak
When asked whether we would publish his writings, we responded yes. Here was a man we knew nothing about, but...
Healthcare’s Others
We think we’re different from other patients with similar conditions. This belief affects our interactions in healthcare.
Irony of Abortion Law
Most abortion laws default to restricting access. But making a clinical behavior more difficult to accomplish does not deter it.
Welcome to Darkness, Dr. Lamartiniere
We pen a personal letter to Dr. Lamartiniere, who is fighting to appeal his conviction for unlawfully prescribing opioids.
Nobody Will Believe You
We dive into the cognitive dissonance physicians face when challenging false narratives surrounding the opioid epidemic.
Healthcare Laws are Oaths
We review the history of healthcare law to see why the original laws were framed as oaths to guide physician...
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more